Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl)amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

Robert S. Bresalier, Robert S. Sandler, Hui Quan et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

Scott D. Solomon, John J.V. McMurray, Marc A. Pfeffer et al. · New England Journal of Medicine · 2005 · 2.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2

Brendan McAdam, Francesca Catella-Lawson, Issam A. Mardini et al. · Proceedings of the National Academy of Sciences · 1999 · 1.3K citations

Medicine, Pharmacology, Pharmacotherapy +13

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery

Nancy A. Nussmeier, Andrew Whelton, Mark T. Brown et al. · New England Journal of Medicine · 2005 · 1.1K citations · Full text

Medicine, Perioperative Medicine, Surgery +11

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 399 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15